Showing results (1-10 of 160) with videos related to
Sort By:
Pageof 16
Best Practice & Research. Clinical Haematology|December 1, 2011
Is a nadir bone marrow required and, if so, what to do with residual disease?Selina M LugerBest Practice & Research. Clinical Haematology|November 30, 2019
Acute myeloid leukemia: How to treat the fit patient over age 75?Selina M LugerBest Practice & Research. Clinical Haematology|November 21, 2017
How can one optimize induction therapy in AML?Selina M LugerHematology. American Society of Hematology. Education Program|January 18, 2011
Treating the elderly patient with acute myelogenous leukemiaSelina M LugerBest Practice & Research. Clinical Haematology|December 6, 2021
Is the current consolidation regimen for AML evidence-based?Selina M LugerJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2021
Consolidation Therapy for Acute Myeloid Leukemia: Defining a BenchmarkSelina M LugerCurrent Opinion in Hematology|January 15, 2016
Revisiting maintenance therapy in acute myeloid leukemia with novel agentsJonathan Canaani, Selina M LugerCurrent Treatment Options in Oncology|January 23, 2017
Minimal Residual Disease in Acute Myeloid LeukemiaPamela J Sung, Selina M LugerCase Reports in Hematology|August 29, 2012
A paraneoplastic syndrome characterized by extremity swelling with associated inflammatory infiltrate heralds aggressive transformation of myelodysplastic syndromes/myeloproliferative neoplasms to acute myeloid leukemia: a case seriesJames K Mangan, Selina M LugerCurrent Treatment Options in Oncology|April 29, 2023
Which Second-Line Tyrosine Kinase Inhibitor(s) for Chronic Myeloid Leukemia?Robert D Schwab, Selina M LugerPageof 16